http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017055592-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a695659dff59e19b48ff41f2a54442dc |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C201-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
filingDate | 2016-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a03faa9af9ecf41d17cb9173ad7d740 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21ce0a502bda3c402cba257180992b48 |
publicationDate | 2017-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2017055592-A1 |
titleOfInvention | 2-aminoquinazoline derivatives as p70s6 kinase inhibitors |
abstract | The invention provides compound that inhibit or modulate the activity of p70S6 kinase, the compounds being of the formula (I) or a salt, tautomer or N-oxide thereof; wherein: one of Y and Z is R 3 and the other is Ar 2 ; Q 1 is an optionally substituted C 1-8 alkylene group; and wherein a carbon atom of the C 1-8 alkylene group may optionally be replaced by a cyclopropane-1,1-diyl or cyclobutane-1, 1-diyl group provided that the total number of carbon atoms in an alkylene group containing such a replacement does not exceed 8; Q 2 is a bond or an optionally substituted C 1-8 a alkylene group R 1 is selected from hydrogen, NR x R y and a group Cy 1 ; R x and R y are each is selected from hydrogen, C 1-4 hydrocarbyl or hydroxy-C 1-4 hydrocarbyl; or NR x R y forms an optionally substituted 4 to 7-membered heterocyclic ring; Cy 1 is an optionally substituted C-linked 3 to 7 membered monocyclic non- aromatic carbocyclic or heterocyclic; R 2 and R 4 are each is selected from hydrogen, fluorine, chlorine, optionally substituted C 1-2 alkyl and optionally substituted C 1-2 alkoxy; R 3 is selected from hydrogen, fluorine, chlorine, optionally substituted C 1-2 alkyl and optionally substituted C 1-2 alkoxy; Ar 1 is an optionally substituted monocyclic 5 or 6-membered aryl or heteroaryl ring; and Ar 2 is an optionally substituted bicyclic 8 to 11 -membered heteroaryl group. The compounds are useful in medicine, for example in the treatment of a disease or condition selected from cancers, neurodevelopmental diseases and neurodegenerative diseases. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4198027-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023055679-A1 |
priorityDate | 2015-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 793.